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Introduction
The circadian clock is an evolutionarily conserved biological 
time-keeping system that synchronizes behavioural and physi-
ological processes to a 24-hour cycle, including cell proliferation 
and metabolism1. The circadian system is recognized to regu-
late host innate and adaptive immune responses to microbial 
pathogens to conserve energy utilization2–8. The circadian sys-
tem comprises a central clock in the suprachiasmatic nucleus of 
the hypothalamus and secondary clocks in the peripheral organs. 
The liver is a highly circadian regulated organ with up to 20% of 
genes under clock control9. Research over the past two dec-
ades has demonstrated that disrupting clock function associates 
with the development of liver diseases, including fatty liver dis-
ease, cirrhosis and hepatocellular carcinoma (HCC), highlighting 
a key role for the circadian system in regulating hepatic 
function9,10.
Viral infection of the liver is a global health problem with up to 
71 million individuals infected with hepatitis C virus (HCV) 
that causes progressive liver disease and is one of the leading 
indications for liver transplantation11. In almost every case HCV 
infects the newly transplanted organ or donor allograft, provid-
ing an unprecedented window to study the early stages of HCV 
infection. We had the opportunity to study the relationship between 
the time of liver transplantation and HCV replication dynam-
ics in subjects enrolled in a clinical trial to assess the safety and 
efficacy of an entry inhibitor targeting scavenger receptor BI 
(SR-BI)12. We noted differences in viral infection of the 
allograft in control subjects that associated with the time of 
liver transplant, suggesting a role for circadian processes to 
regulate HCV entry into the liver.
Results
HCV infection of the newly transplanted graft is reported to 
show “rapid” or “slow” early phase replication kinetics 
(Figure 1)13,14, however, the host pathways defining these profiles 
are not well understood. To investigate whether HCV replication 
kinetics is influenced by the time of transplant, patients in the 
untreated arm of the trial were grouped according to their time of 
surgery between the hours 6am–1pm (AM) (n=6) or 2pm–11pm 
(PM) (n=7). No patients were transplanted during the night 
(11pm–6am). Transplantation was required for liver failure (n=8) 
or HCC (n=5). Patients were infected with HCV genotype (Gt) 1 
(7 patients) or Gt3 (4 patients), with single cases of Gt2 and 
Gt4. No significant differences in baseline median HCV RNA 
load were observed (5.4 log
10
 IU/ml) (Table 1)15. Additional 
clinical parameters previously reported to affect HCV repli-
cation or allograft survival, such as donor age (AM: median, 
55 years; range 45–69 years; PM: median, 44 years; range, 
29–64)16, cold-ischemia time17, duration and time of operation18 
were comparable in the AM or PM groups (Table 1). In four of 
six patients (#3, 7, 8 and 11) in the AM group, a viral rebound 
toward pre-transplant levels was observed during the time of 
study (Figure 2A). In contrast, none of the seven patients 
transplanted in the PM group showed a recovery of viral load to 
pre-transplant levels (Figure 2B).
Combining the replication kinetics from control subjects within 
AM or PM groups enabled us to apply lines of best fit and to 
conclude that the differences in replication kinetics were signifi-
cant (Figure 3A) (F-test, p<0.001). A similar analysis of patients 
receiving the SR-BI antagonist ITX5061 failed to show any sig-
nificant difference in replication kinetics between the AM (n=4) 
or PM (n=6) groups (Figure 3B), suggesting a role for circadian 
regulation of HCV entry.
Figure 1. Schematic of hepatitis C virus (HCV) replication 
kinetics in the first week following liver transplant. 
Representative plasma HCV RNA levels are shown over the first 
week post-transplant. The declining values observed in the first 24 h 
following the post-anhepatic (PA) phase represent viral clearance 
(blue shading) from the periphery. Infection of the allograft results 
in a subsequent increase in viral RNA that can occur with either 
‘rapid’ (A) or ‘slow’ (B) kinetics (pink shading). The horizontal 
dashed line represents the plasma viral load pre-transplant and 
allows us to quantify viral replication kinetics by measuring the area 
under the curve (AUC) (the hatched area), a patient showing rapid 
infection will result in a smaller AUC value compared to one with 
slower kinetics.
      Amendments from Version 1
In this revision we have responded to 3 points raised by the 
referees by : 
1)    Replacing reference 11 with a newer estimate of HCV 
incidence rates and updating the number in the text.
2)    Rewording the text describing Figure 3B to use the word 
“suggesting” rather than “supporting”
3)    Inserting into the legend for Figure 3 the numbers of 
patients in each graph.
See referee reports
REVISED
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Table 1. Cohort data. Values shown for continuous variables are 
means (standard deviations).
Variable AM (n=6) PM (n=7)
Age, years 53 (11) 54 (7)
Sex
   Male 5 6
   Female 1 1
Ethnicity
   Caucasian 4 5
Weight, kg 85 (11) 82 (16)
Indication for transplant
   Liver failure 3 5
   HCC 3 2
MELD score 13 (4.5) 15 (3.7)
Initial HCV RNA, log10 IU/ml 5.0 (1.5) 5.7 (0.6)
Genotype
   Gt1 2 5
   Non-Gt1 4 (2 Gt3, 1 Gt2, 1 Gt4) 2 (2 Gt 3)
Donor data
   Age, years 56 (8) 45 (11)
   Cold Ischaemic time, mins 534 (64) 583 (142)
   Duration of operation, h¶ 5.7 (2.0) 4.5 (0.8)
¶Duration estimated between the start of anhepatic phase and arrival on 
intensive care unit. One patient’s operation (AM) was 10 hours, all others 
were 4–6 hours. HCC, hepatocellular carcinoma; MELD, model for end-stage 
liver disease; HCV, hepatitis C virus.
We12 and others13,14 have previously reported a rapid decrease 
in HCV RNA within the first 16 hours following surgery due 
to clearance of virus in the periphery by the reticular endothe-
lial system of the new liver. To assess the influence of transplant 
time on viral clearance and allograft infection kinetics we cal-
culated the area over the infection curve for control and treated 
subjects between 0–16 h and 24–168 h after transplantation 
(Figure 3C, D). Time of transplant had minimal effect on viral 
clearance in all subjects (Figure 3C, D). Control patients in the AM 
group showed higher rates of infection than those in the PM group, 
whereas this pattern was not apparent in the ITX5061-treated 
groups (AM, n=6; PM, n=4) and response to therapy was not 
time-dependent (Figure 3C, D). Structuring the data in this 
manner did not reach significance and this most likely reflects 
the small number of data points analysed relative to the earlier 
regression analysis (Figure 3A, B). In summary, these data 
support an association between HCV allograft infection rate and 
time of liver transplantation.
Discussion
Our observation that the time of day of liver transplantation is 
associated with HCV allograft infection kinetics supports a role 
for circadian components to regulate host pathways important 
for HCV entry and replication. This observation has biologi-
cal plausibility, since factors known to control both HCV entry 
and replication are reported to be under circadian control. For 
example, the tight junction proteins occludin and claudin-1, which 
define HCV entry into hepatocytes, have been reported to be cir-
cadian regulated in the colon19, supporting a model where HCV 
entry into the liver may be circadian regulated. Similarly, the abun-
dant liver-specific microRNA, miR-122, an essential host factor 
required for HCV RNA replication, is circadian regulated, and 
miR122 targeted genes showed clear circadian profiles20, providing 
a further pathway for circadian control of HCV RNA replication.
Natural killer cells21 and interferons22 are major contributors to 
anti-viral responses, and are reported to be circadian regulated. 
In the context of liver transplantation, where recipients are 
immunosuppressed, the impact of recipient or allograft innate 
and adaptive immunity may be compromised, suggesting that 
differences in viral kinetics may reflect differences in hepatocel-
lular permissivity to support HCV infection.
We recognize the limitations of this analysis, particularly with 
respect to the small number of patients studied. There are 
obvious ethical constraints in accessing donor liver tissue to 
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Figure 2. Hepatitis C virus (HCV) replication kinetics in control subjects in the AM or PM transplant groups. HCV RNA levels were 
quantified in subjects undergoing liver transplant in the AM (A) or PM (B) groups, with data expressed relative to the mean value of three 
samples collected after admission to hospital and before surgery. Samples were collected at 0, 4, 8, 12, 16 and 24 h post-transplant and 
daily thereafter for 7 days (168 h).
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assess its circadian status. However, to the best of our knowledge 
this is the first report highlighting a potential role for liver 
time-of-day regulated pathways to modulate HCV replication 
in vivo and this has clear translational potential for other 
hepatotropic infectious agents and the design of therapeutics.
Methods
Subjects
The data presented were obtained from subjects enrolled in an 
open-label phase 1b study to assess the effect of ITX5061 in 
patients undergoing liver transplantation at a single centre (Queen 
Elizabeth Hospital Birmingham, Birmingham, UK), described 
previously12. All patients gave informed written consent and 
ethical approval was given by the UK National Research 
Ethics Service (reference 10/H0301/36)12. The study was regis-
tered at clinicaltrials.gov (NCT01292824). The study enrolled 
men and women between the ages of 18 and 65 years who were 
suitable for liver transplantation. Patients with HCV-associated 
end-stage liver disease or HCC were enrolled regardless of 
their infecting Gt or previous anti-viral treatment. Patients 
co-infected with HBV or human immunodeficiency virus were 
excluded, as were patients receiving a liver from a HCV-positive 
donor.
Plasma collection and analysis
Plasma was collected at screening, before surgery, at the time 
of transplantation, and during a follow-up period of 90 days. 
HCV RNA levels were measured on admission to the hospital, 
immediately following the induction of anesthesia, at the 
time of portal vein clamping (the start of the anhepatic phase), 
immediately before perfusion of the allograft, and 1 hour later. 
Plasma samples were collected every 4 hours during the first 
post-transplant day, daily for the first week, weekly for the first 
month, and monthly thereafter up to 90 days. Plasma HCV RNA 
was measured using the COBAS TaqMan HCV test version 2.0 
(Roche Diagnostics Ltd., Switzerland) in a laboratory accredited 
Figure 3. Effect of liver transplantation time on hepatitis C virus (HCV) clearance and early replication kinetics in control (n=13) and 
ITX5061 (n=10) treated subjects. The decline in HCV RNA levels in control (A) and ITX5601 treated (B) subjects in AM (blue) and PM (red) 
groups were averaged at each time point, plotted and lines of best fit calculated. Statistical comparison (F-test) showed a significant difference 
between viral replication in the control AM and PM groups (p<0.001). Patients were assessed for viral clearance (0–16 h) and infection kinetics 
(24–168 h) by determining the AUC over time in control (C) and ITX5601 treated (D) subjects where each symbol represents a patient. Groups 
were compared using a student’s unpaired t-test and no significant difference was observed.
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by the Health Protection Agency UK. Data were analysed using 
t-tests or F-tests in GraphPad Prism 7.0 software.
Data availability
Raw data for the study, including demographic informa-
tion for untreated transplant patients and hepatitis C virus 
RNA levels in untreated and ITX5061-treated groups, 
are available on OSF: http://dx.doi.org/10.17605/osf.io/kjnhr15. 
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
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None of the patients in Fig.2 received ITX5061. The treated patients are only shown in
Fig.3B, this is now stated in the figure legend.
The number of patients in each group should be indicated in Figure 3.




Clinical information for the ITX5061 treated patients was previously published (Rowe 2016)




ITX5061 administration details were provided in our earlier report (Rowe 2016) and we cited
this publication rather than duplicating data in current report.
How does the timing reflect doses of immunosuppression given?  Could this also have an
effect on the post-transplant kinetic? 
All patients arriving at the intensive care unit received standard immunosuppressive therapy
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All patients arriving at the intensive care unit received standard immunosuppressive therapy
of corticosteroids together with tacrolimus and azathioprine (details provided in Rowe
2016). Since our report studied HCV replication in the first week post-transplant when
patients received the same immunosuppressive regimen we can exclude this parameter as
a confounding influence.
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